Comparison between Lovastatin and Cholestyramine in the Treatment of Moderate to Severe Primary Hypercholesterolaemia

References

• Tyroler H A. Review of lipid-lowering clinical trials in relation to observation epidemiological studies. Circulation 1987; 76: 515–22
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–74
   PubMed Web of Science ®Google Scholar
• Rifkind B M. Clinical trials of cholesterol lowering. Atheroscler Rev 1988; 18: 59–70
   Google Scholar
• Connor W E, Connor S L. The dietary treatment of hyperlipidemia: Rationale, technique, and efficacy. Med Clin North Am 1982; 66: 485–518
   PubMed Web of Science ®Google Scholar
• Havel R J, Hunninghake D B, Illingworth D R, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: A multicenter study. Ann Intern Med 1987; 107: 609–15
   PubMed Web of Science ®Google Scholar
• Hoeg M J, Maher M B, Zech L A, et al. Effectiveness of mevinolin on plasma lipoprotein concentration in type II hyperlipoproteinemia. Am J Cardiol 1986; 57: 933–9
   PubMed Web of Science ®Google Scholar
• Lovastatin study group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. JAMA 1986; 256: 2829–34
   PubMed Web of Science ®Google Scholar
• Lovastatin study group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 1988; 260: 359–66
   PubMedGoogle Scholar
• Ma P T, Gil G, Sudhof T C, et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNAforlow-density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986; 83: 8370–74
   PubMed Web of Science ®Google Scholar
• Illingworth D R. Mevinolin plus colestipol in therapy for severe heterozygousfamilial hypercholesterolemia. Ann Int Med 1984; 101: 598–604
   PubMed Web of Science ®Google Scholar
• Leren T P, Hjermann I, Kåre B, Leren P, Foss O P, Viksmoen L. Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproleins in heterozygotes for familial hypercholesterolemia. Atherosclerosis 1988; 73: 135–41
   PubMed Web of Science ®Google Scholar
• Illingworth D R, Sexton G J. Hypocholesterolemic Effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 1984; 74: 1972–8
   Google Scholar
• Report of the National Cholesterol Education Program Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148: 36–69
   PubMed Web of Science ®Google Scholar
• Röschlau P, Bernt E, Gruber W. Enzymatische Bestimmung des Gesamtcholesterins im Serum. Z Klin Chem Klin Biochem 1974; 12: 403–7
   PubMedGoogle Scholar
• Wahlefeld A W. Triglycerides. Determination after enzymatic hydrolysis. Methods in enzymatic analysis., H U Bergmeyer. Academic press, New York 1974; 1831–5
   Google Scholar
• Penttilä I M, Voutilainen E, Laitinen P, Juutilainen P. Comparison of different analytical and precipitation methods for the direct estimation of serum high-density lipoprotein cholesterol. Scand J Clin Lab Invest 1981; 41: 353–60
   PubMed Web of Science ®Google Scholar
• Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–552
   PubMed Web of Science ®Google Scholar
• Avogaro P, Bon G B, Cazzolato G, Quinci G B. Are apolipoproteins better discriminators than lipids for atherosclerosis?. Lancet 1979; i: 901
   Google Scholar
• Fruchart J C, Kora I, Cachera C, Clavey V, Duthilleul P, Moschetto Y. Simultaneous measurement of plasma apolipoproteins A—I and Bby electroimmunoassay. Clin Chem 1982; 28: 59–61
   PubMedGoogle Scholar
• Iman R L. A power of a rank transform for the two-way classification model when interaction may be present. Can J Stat 1974; 2: 227–39
   Google Scholar
• Bradford R H, Shear C L, Chremos A N, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch intern Med 1991; 151: 43–9
   PubMed Web of Science ®Google Scholar
• Witztum J L, Schonfeld G, Wiedman S W, et al. Bile sequestrant therapy alters the composition of low-density and high-density lipoproteins. Metabolism 1979; 28: 221–9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Packard C J, Bicker S, et al. Cholestyramine promotes receptor-mediated low-density lipoprotein catabolism. N Engl J Med 1980; 302: 1219–22
   PubMed Web of Science ®Google Scholar
• Durrington P, Bolton C, Hartog M. Serum and lipoprotein apolipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 1978; 82: 151–60
   PubMed Web of Science ®Google Scholar
• Young S G, Witztum J L, Casal D C, et al. Conservation of the low-density lipoprotein receptor-binding domain of apolipoprotein B. Arteriosclerosis 1986; 6: 178–88
   Google Scholar
• Bilheimer D W, Grundy S M, Brown M S, et al. Mevinolin and colestipol stimulate receptor-mediated clearance of low-density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983; 80: 4124–8
   PubMed Web of Science ®Google Scholar
• Grundy S M, Vega G L. Influence of mevinolin on metabolism of low-density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 1985; 26: 1464–75
   PubMedGoogle Scholar
• Tobert J A. New developments in lipid-lowering therapy: The role of inhibitors of HMG-CoA reductase. Circulation 1987; 76: 534–8
   PubMed Web of Science ®Google Scholar
• Brown M S, Goldstein J L. Drugs used in the treatment of hyperlipoproteinemias. The Pharmacological Basis of Therapeutics., A G Gilman, L S Goodman, T W Rall, et al. Macmillan Publishing Co Inc, New York 1985; 827–45
   Google Scholar
• Hunninghake D B. Clinical trials of lovastatin and simvastatin versus cholestyramine. Atheroscler Rev 1988; 18: 133–8
   Google Scholar
• Castelli W, Abbott R, McNamara P. Summary estimates of cholesterol used to predict coronary heart disease. Circulation 1983; 67: 730–734
   PubMed Web of Science ®Google Scholar
• Grundy S M, Ahrens E H, Jr., Salen G T. Interruption of the enterohepatic circulation of bile acids in man: Comparative effects of cholestyramine and ideal exclusion of cholesterol metabolism. J Lab Clin Med 1971; 78: 94–121
   PubMed Web of Science ®Google Scholar
• Hamprecht Back P. B., Lynen F. Regulation of cholesterol biosynthesis in rat liver: Diurnal changes in activity and influence of bile acids. Arch Biochem Biophys 1969; 133: 11–21
   Google Scholar
• Beil U, Crouse J R, Einarsson K, et al. Effects on interruption of the enterohepatic circulation of bile acids on the transport of very low-density lipoprotein triglycerides. Metabolism 1982; 31: 438–44
   PubMedGoogle Scholar
• Norman D J, Illingworth D R, Munson J, et al. Myolysis and acute renal failure in a heart-transplant patient receiving lovastatin. N Engl J Med 1988; 318: 46–7
   PubMed Web of Science ®Google Scholar
• East C, Alvizatos P A, Grundy S M, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47–8
   PubMed Web of Science ®Google Scholar
• Tobert J A. Reply. N Engl J Med 1988; 318: 48
   PubMed Web of Science ®Google Scholar
• Hunninghake D B, Miller V T, Goldberg I, et al. Lovastatin. Follow-up ophtalmologic data. JAMA 1988; 259: 354–5
   PubMed Web of Science ®Google Scholar